在初始治療的T2DM患者以及二甲雙胍單藥治療血糖控制不佳的T2DM患者中開展的Ⅲ期臨 床試驗證實，普盧格列汀具有良好的有效性和安全性。與二甲雙胍單藥治療相比，普盧格 列 汀 聯 合 二 甲 雙 胍 具 有 顯 著 且 持 久 的 降 糖 作 用 ， 低 血 糖 發 生 率 較 低 ， 且 安 全 性 良 好 。 此 外，該產品與其他藥物發生相互作用的可能性較低，輕中度腎功能不全患者服用該產品時 無需調整劑量。與兩種單方製劑聯合應用相比，複方製劑可簡化治療方案、顯著提高患者 依從性，從而更有效地控制血糖。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 普盧格列汀二甲雙胍緩釋片的上市申請 獲國家藥監局受理 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 ...

Core Viewpoint - The collaboration between Haixiang Pharmaceutical and Wanbangde Pharmaceutical Group focuses on developing innovative drugs for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, leveraging each company's strengths to enhance their market competitiveness [1] Group 1: Collaboration Details - Haixiang Pharmaceutical signed an "Innovative Drug Cooperation Agreement" with Wanbangde Pharmaceutical on January 12, 2023 [1] - The initial collaboration will focus on the WP205 product, which has received orphan drug designation, and its research and commercialization [1] - Future cooperation will involve small molecule cyclic peptide agonists targeting melanocortin receptors (MCR) in areas such as raw materials and formulations [1] Group 2: Strategic Implications - The partnership aims to effectively integrate resources and complement each other's strengths in the innovative drug sector [1] - Haixiang's involvement in the neurodegenerative disease drug development will expand and deepen its presence in the peptide drug field [1] - This collaboration is expected to enhance Haixiang's existing research pipeline and positively impact its innovative development, thereby improving future market competitiveness [1]

Core Viewpoint - Haishang Pharmaceutical has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical to collaborate on the research and commercialization of the WP205 product for amyotrophic lateral sclerosis (ALS) [1] Group 1: Agreement Details - The agreement involves Haishang Pharmaceutical providing 150 million yuan in funding for the development of the WP205 product [1] - Haishang Pharmaceutical will receive 15% of the revenue rights from the commercialization of the product [1] - The agreement is subject to approval by the shareholders' meeting of Wanbangde Pharmaceutical [1] Group 2: Risks - There are risks associated with regulatory policies and market environment that could impact the collaboration [1] - The high-risk nature of drug development is highlighted as a potential concern [1]

Core Viewpoint - The company,艾力斯 (688578.SH), emphasizes its commitment to innovation as a core competitive advantage and outlines its strategic focus on the development of its key product,伏美替尼, along with other innovative drug candidates [2]. Group 1: Product Development - The company is conducting in-depth research on伏美替尼, exploring multiple application scenarios beyond the already approved indications for second-line and first-line treatments [2]. - Ongoing clinical registrations for伏美替尼 include auxiliary treatment for classic EGFR mutations, second-line and first-line treatments for 20 exon mutations, PACC mutation indications, brain metastasis indications, and auxiliary treatment for non-classic EGFR mutations [2]. - The NDA application for the second-line treatment of the 20 exon mutation has been accepted and prioritized for review, while the PACC mutation NSCLC first-line treatment indication is expected to be classified as a breakthrough therapy by December 2025 [2]. Group 2: New Product Introductions - In August 2024, the company introduced the KRAS G12C inhibitor,戈来雷塞, and the SHP2 inhibitor, taking full responsibility for their subsequent development [2]. - The second-line treatment indication for戈来雷塞 in NSCLC was officially approved in May 2025, and ongoing studies are being conducted for its use in pancreatic cancer and other solid tumors [2]. - Clinical trials are progressing smoothly for the combination of戈来雷塞 with the SHP2 inhibitor for first-line treatment of KRAS G12C mutation non-small cell lung cancer [2]. Group 3: Research and Development Enhancements - The company is advancing its new drug discovery platform, enhancing its capabilities in both large and small molecule research, and strengthening team development [2]. - Several innovative drugs are currently in the preclinical research stage, indicating a robust pipeline for future growth [2]. - The company is committed to promoting the internationalization of its products, aiming to make innovative drugs accessible to patients worldwide [2].

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for clinical trials of IMM01 (Tida-paisip) for the treatment of atherosclerosis, marking a significant milestone in its product development [1] Group 1: Product Development - IMM01 (Tida-paisip) is an innovative targeted CD47 molecule and the first SIRPα-Fc fusion protein to enter clinical stages in China [1] - The product activates macrophages through a dual mechanism by blocking the "don't eat me" signal and delivering the "eat me" signal via Fc-gamma receptors [1] - The CD47 binding domain of IMM01 has been specially modified to avoid binding with human red blood cells, enhancing its safety profile [1] Group 2: Regulatory Milestones - IMM01 (Tida-paisip) has been granted orphan drug designation by the FDA for first-line treatment of CMML in combination with Azacitidine as of November 2023 [1] Group 3: Intellectual Property - The company holds global intellectual property and commercialization rights for IMM01 (Tida-paisip), with a patent family that includes granted patents in China, the United States, Japan, and the European Union [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 – 1 – 本集團擁有IMM01（替達派西普）的全球知識產權及商業化權利。截至本公告日 期，就IMM01（替達派西普）而言，本集團擁有一個專利家族，其中包括在中國、 美國、日本及歐盟的已授權專利。 根據香港聯合交易所有限公司證券上市規則第18A.05條的警示聲明：本公司無 法保證能夠成功開發或最終上市銷售IMM01（替達派西普）。本公司股東及潛在 投資者在買賣本公司股份時應謹慎行事。 承董事會命 宜明昂科生物醫藥技術（上海）股份有限公司 自願公告 IMM01（替達派西普）獲國家藥監局批准進行 動脈粥樣硬化治療的臨床試驗 本公告由宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」，連同其附屬 公司統稱「本集 ...

Core Viewpoint - Chengdu XianDao is positioned as an innovative technology-driven biotechnology company, focusing on drug discovery and optimization through advanced platforms and technologies, including a large DNA-encoded small molecule library and AI integration [2][4][12]. Company Overview - Chengdu XianDao is a leading innovative biopharmaceutical company with the world's largest known DNA-encoded small molecule library, focusing on small molecule and nucleic acid drug discovery and optimization [2]. - The company has developed several core technology platforms, including DNA-encoded library (DEL) technology, fragment-based drug design (FBDD/SBDD), oligonucleotide-based drug development (OBT), and targeted protein degradation (TPD) [2][3]. Technological Capabilities - The company is constructing an automated closed-loop DEL+AI+automated DMTA (Design-Synthesis-Testing-Analysis) molecular optimization platform to accelerate the discovery and optimization of preclinical drug candidates [3]. - Chengdu XianDao's DEL technology allows for high-throughput screening of over 120 billion small molecules, significantly enhancing the efficiency of drug discovery [2][15]. Market Trends and Strategic Focus - The global biopharmaceutical industry is rapidly expanding, with a notable increase in innovative drug approvals. In 2024, the FDA approved 50 new drugs, with 32 being new chemical entities [7][8]. - Chengdu XianDao is strategically focusing on high-potential therapeutic areas such as oncology, inflammation, and autoimmune diseases, with the global oncology drug market projected to reach $304.8 billion by 2025 [8][9]. AI Integration in Drug Development - The company is leveraging AI to enhance drug discovery processes, focusing on building predictive models for compound affinity and optimizing molecular design through automated systems [12][13]. - However, challenges remain in fully integrating AI into drug development, with current applications primarily serving as research aids rather than providing systematic predictive outcomes [15][17]. Business Model and Growth Strategy - Chengdu XianDao aims to establish a sustainable and profitable business model by balancing its own drug pipeline with collaborative research projects, ensuring compliance with commercial rules and avoiding conflicts of interest with clients [6][7]. - The company emphasizes the importance of generating revenue growth to support its business expansion and technological advancements [7].

Summary of Haizhi Science Conference Call Company Overview - **Company**: Haizhi Science (海思科) - **Key Focus**: Development and commercialization of innovative pharmaceuticals, particularly in the respiratory system and oncology sectors Key Industry Insights - **Collaboration with Frasier**: Haizhi Science is collaborating with Frasier to advance the clinical development and commercialization of PD34 in the U.S. Frasier has raised $220 million to support Phase I and II clinical trials, aiming for FDA approval by 2030 [2][4] - **Market Strategy**: The partnership with Frasier allows Haizhi Science to retain rights in the Chinese market while leveraging Frasier's expertise in respiratory drug development and funding capabilities [2][5] - **International Business Development (BD)**: Previous licensing agreements for TYK2 and DTP1 with Alumis and Casey demonstrate Haizhi Science's BD strength and lay the groundwork for future international collaborations [2][6] Core Product Development - **PD34 Potential**: PD34 is projected to have peak sales in the billions if successfully commercialized. The collaboration with Frasier is expected to accelerate its entry into the U.S. market [2][7] - **Clinical Trials**: Key Phase II data for PD34 is expected to be disclosed in early 2026, with plans for Phase III trials to follow. The company anticipates submitting a New Drug Application (NDA) in China by late 2027 or early 2028 [2][9] - **DPI Product 39,004**: This product is designed to meet various usage scenarios and has shown promising initial efficacy in clinical trials. It combines mixed rotation and DPI (dry powder inhaler) technologies [2][9] Financial Aspects - **Revenue Sharing**: Haizhi Science will receive a double-digit percentage of revenue from licensing agreements based on the development stage of assets in the U.S. [2][8] - **Future Licensing Opportunities**: The company plans to pursue additional licensing agreements and aims to report a new product by the end of 2026, with two to three more expected in 2026 [3][21] Competitive Landscape - **Differentiation**: 39,004 offers advantages over competitors by addressing various treatment backgrounds and demonstrating effective results in complex patient populations [2][9] - **Market Positioning**: Haizhi Science is strategically avoiding highly competitive areas in the domestic market while focusing on therapeutic areas like anesthesia, metabolism, and respiratory diseases [19] Future Directions - **Long-term Vision**: The company aims to transform into an innovative drug company over the next decade, focusing on unique and challenging products rather than generic competition [17][22] - **International Expansion**: Haizhi Science is committed to expanding its international presence and learning from global market leaders to enhance its competitive edge [16][19] Recent Achievements - **Product Pipeline**: Haizhi Science has four key molecules in development, with significant progress in clinical trials and regulatory submissions expected in the coming years [3][13][23] - **Market Recognition**: The company has successfully integrated several products into the healthcare system and is actively pursuing international collaborations [23] Conclusion - **Commitment to Innovation**: Haizhi Science is focused on advancing its product pipeline and expanding its market reach through strategic partnerships and innovative drug development, positioning itself for significant growth in the pharmaceutical industry [21][22]

Core Viewpoint - The announcement highlights the inclusion of DR10624, a novel long-acting tri-target agonist developed by Zhejiang Daor Bio, in the list of breakthrough therapies for severe hypertriglyceridemia (sHTG), indicating significant potential for addressing this public health issue [1]. Group 1: Product Development and Clinical Research - DR10624 is a first-in-class tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, with clinical research approvals from China's CDE and the US FDA for sHTG [1]. - The Phase II clinical study (DR10624-201) results are set to be presented at the 2025 American Heart Association Scientific Sessions, showcasing its innovative approach in treating sHTG [1]. Group 2: Clinical Efficacy and Safety - Clinical data from the DR10624-201 study demonstrate strong lipid-lowering effects and good safety profiles, with additional benefits in reducing liver fat and metabolic regulation [2]. - Traditional lipid-lowering medications have limited efficacy in reducing triglyceride levels below 500 mg/dL, highlighting the need for more effective treatments like DR10624 [2]. Group 3: Public Health Implications - The increasing prevalence of hypertriglyceridemia, with approximately 10% of adults affected globally, underscores the urgent need for better therapeutic options for sHTG, which is associated with serious health risks [2][3]. - DR10624's potential to significantly lower triglycerides and improve inflammatory lipid profiles positions it as a promising innovative therapy for sHTG and related metabolic diseases [3].

Core Viewpoint - Guangzhou's Huangpu and Tianhe districts are focusing on the biopharmaceutical sector, showcasing innovative drugs and leveraging AI technology to enhance drug development efficiency [1][2][6]. Group 1: Innovative Drug Development - The innovative drug AR882 by Yipin Hong Pharmaceutical demonstrates significant efficacy in treating gout, filling a gap in oral small molecule medications [1][2]. - By 2025, China's innovative drug BD transaction scale is expected to account for 49% of the global market, with Guangzhou enterprises becoming key players in the global innovation network [2]. - Baiyoutai has achieved overseas authorization for five products totaling $750 million, with a goal of doubling annual revenue starting in 2026 and aiming for 15 global product launches by 2030 [3]. Group 2: AI Integration in Biopharmaceuticals - AI technology is becoming a crucial driver for the biopharmaceutical industry, enhancing research and production capabilities [6][7]. - Collaborations between local hospitals and AI companies aim to streamline drug discovery processes, significantly reducing the time from basic research to clinical trials [6][7]. - The global pharmaceutical AI market is projected to grow from over $4 billion in 2025 to $25.7 billion by 2030, indicating vast potential for AI in drug development [8]. Group 3: Supportive Ecosystem and Policies - The establishment of the National University Regional Technology Transfer Center in the Guangdong-Hong Kong-Macao Greater Bay Area is accelerating the transformation of research results into practical applications [5]. - Policies such as expedited approval for innovative medical devices and R&D incentives are fostering a conducive environment for biopharmaceutical innovation [4].